Financial Results, Reports & Presentations

Below you can find financial results, reports, presentations, IPO and more.

DKK ('000) unless otherwise stated	Q2, 2020	Q2, 2019	% change	Q1-Q2, 2020	Q1-Q2, 2019	% change	2019
INCOME STATEMENT
Net revenue	760	1,465	-48%	1,205	2,571	-53%	3,582
EBIT (operating profit/loss)	-4,562	-4,594	-1%	-10,995	-8,457	30%	-19,723
Net profit/loss for the period	-4,358	-4,350	0%	-10,545	-8,024	31%	-18,797
BALANCE SHEET
Non-current assets	608	335	81%	608	334	82%	715
Current assets	43,089	56,075	-23%	43,089	56,075	-23%	44,442
Equity	39,505	52,987	-25%	39,505	52,987	-25%	42,215
Non-current liabilities	0	0	-	0	0	-	0
Current liabilities	4,192	3,432	22%	4,192	3,423	22%	2,942
CASH FLOW STATEMENT
Cash flow from operating activities	-4,128	-5,660	-27%	-9,812	-9,547	3%	-18,072
Cash flow from investing activities	0	-167	-100%	0	-371	-100%	-603
Cash flow from financing activities	7,835	0	-	7,835	0	-	0
Net cash flow	3,707	-5,827	-164%	-1,977	-9,919	-80%	-18,675
OTHER KEY FIGURES AND RATIOS
Cash end-of-period	39,431	50,165	-21%	39,431	50,165	-21%	41,408
Average number of employees, ultimo period (no.)	13	10	30%	13	10	30%	12
Earnings per share before dilution (DKK/share)	-1.43	-1.43	0%	-3.47	-2.64	31%	-6,19
Earnings per share after dilution (DKK/share)	-1.26	-1.26	0%	-3.04	-2.31	31%	-5,43
Number of shares before dilution (#)	3,125,426	3,034,347	3%	3,125,426	3,034,347	3%	3,034,347
Number of shares after dilution (#)	3,342,117	3,464,421	-4%	3,342,117	3,464,421	-4%	3,465,988
Equity ratio (%)	90%	94%	-4%	90%	94%	-4%	93%

Annual Report 2019

In 2019, ViroGates achieved many significant milestones, including four new clinical routine customers, a pipeline of +50 hospitals evaluating the implementation of suPAR in clinical routine practice, and validation on all commercially relevant Roche Diagnostics cobas instruments. All these achievem

Financial Results, Reports & Presentations

Interim Report, Q2 2020

Interim Report, Q2 2020

Financial Results, Q2 2020

Financial Results, Q2 2020

Annual Report 2019

Annual Report 2019